Wistar Institute Appointed Ronny Drapkin as CEO
The Philadelphia-based research center tapped Ronny Drapkin to replace outgoing leader Dario Altieri.
Updated on Oct. 6, 2026 in People
Live Poll
Do you trust local biomedical research institutions to successfully manage their leadership and long-term scientific mission?
The Wistar Institute in University City has named Ronny Drapkin as its new chief executive officer. Drapkin will officially assume the position on November 30, 2026, succeeding Dario Altieri.
Why it matters
The transition marks a leadership change for the independent research center, which manages significant investments in medical infrastructure and viral disease studies in Philadelphia.
The Wistar Institute reported $72 million in total revenue last year and employs 41 lead scientists. This year, the organization expanded its faculty by hiring six new principal investigators.
The players
Ronny Drapkin
He is the incoming chief executive officer of the Wistar Institute who previously conducted research at the University of Pennsylvania.
Dario Altieri
He is the outgoing chief executive officer of the Wistar Institute who served in the leadership role for 11 years.
Wistar Institute
It is an independent biomedical research organization located in Philadelphia's University City neighborhood.
The details
Ronny Drapkin will transition his existing research laboratory from the University of Pennsylvania to the Wistar Institute headquarters. Outgoing CEO Dario Altieri, who announced his plans to step down in January 2026, concludes an 11-year leadership tenure.
Timeline
Dario Altieri announced his departure plans in January 2026.
Ronny Drapkin officially begins his role as CEO on November 30, 2026.
Market Landscape
The leadership change follows a period of growth at the Wistar Institute, including a $24 million investment in the HIV Cure and Viral Diseases Center. The institute continues to compete for top research talent, having added six new principal investigators this year.
The change in leadership does not immediately alter daily operations for the public or current research clinical trials. Patients involved with existing Wistar programs should expect business as usual during the transition period.
The takeaway
The arrival of a new CEO often signals a pivot in institutional research priorities and grant-seeking strategies. Observers should monitor the institute for shifts in recruitment focus or new partnership announcements in the coming year.
Further reading
For more on organizational changes in the region, visit the Philadelphia People section.
Source note: This article includes information reported by The Philadelphia Inquirer.
Live Poll
Do you trust local biomedical research institutions to successfully manage their leadership and long-term scientific mission?
